https://doi.org/10.4081/ecj.2021.9888
Steroids in severe COVID-19 patients: A retrospective analysis on the first pandemics in Lombardy
Submitted: 3 June 2021
Accepted: 16 August 2021
Published: 21 September 2021
Accepted: 16 August 2021
Abstract Views: 592
PDF: 251
Appendix: 75
Appendix: 75
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The pathogenesis of COVID-19 appears to be characterized by a dysregulated immune response. During the first pandemic wave in Lombardy, we started to administer glucocorticoids to some patients with severe respiratory failure requiring support with Continuous Positive Airway Pressure (CPAP) therapy. We retrospectively collected data to identify the effect of glucocorticoids in this COVID-19 particular population. With a multidisciplinary consensus, we administered to selected patients with severe COVID-19 disease (PaO2/FiO2 159±71 mmHg) 0,91 mg/kg/die of methylprednisolone equivalent dose after a median of 8 days of hospitalization. In our study we compared 57 patients from the steroid group with 123 from the control group: the event of invasive mechanical ventilation or death was reduced by 43% between steroid group and control group (19.3 % vs. 34.1 % respectively, p=0.001) and mortality was reduced by about 31% between steroid and usual care alone (15.8 % vs. 22.8 % respectively, p=0.011). Corticosteroids in selected COVID-19 patients may have a relevant impact on outcome, better profiling of the heterogeneity of this disease may be essential to guarantee the best treatment choices.
Arabi YM, Chrousos GP, Meduri GU. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Intensive Care Med 2020;46:2067-70.
DOI: https://doi.org/10.1007/s00134-020-06223-y
Cano EJ, Fonseca Fuentes X, Corsini Campioli C, et al. Impact of Corticosteroids in coronavirus disease 2019 outcomes: systematic review and meta-analysis. Chest 2021;159:1019-40.
DOI: https://doi.org/10.1016/j.chest.2020.10.054
Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med 2020;383:2255-73.
DOI: https://doi.org/10.1056/NEJMra2026131
Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA 2020;324:1307-16.
DOI: https://doi.org/10.1001/jama.2020.17021
The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693-704.
DOI: https://doi.org/10.1056/NEJMoa2021436
Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020; 324:1330-41.
DOI: https://doi.org/10.1001/jama.2020.17023
National Institutes of Health. COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health, 2020. Available from: https://www.covid19treatmentguidelines.nih.gov/
Keller MJ, Kitsis EA, Arora S, et al. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. J Hosp Med 2020;15:489-93.
DOI: https://doi.org/10.12788/jhm.3497
Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: A systemic review and a clinician’s perspective. Diabetes Metab Syndr 2020;14:971-8.
DOI: https://doi.org/10.1016/j.dsx.2020.06.054
Bartoletti M, Marconi L, Scudeller L, et al. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. Clin Microbiol Infect 2021;27:105-11.
DOI: https://doi.org/10.1016/j.cmi.2020.09.014
Tortajada C, Colomer E, Andreu-Ballester JC, et al. Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and intensive care unit admission in patients with COVID-19 according to patients’ oxygen requirements. J Med Virol 2021;93:1817-23.
DOI: https://doi.org/10.1002/jmv.26635
Chroboczek T, Lacoste M, Wackenheim C, et al. Corticosteroids in patients with COVID-19: what about the control group? Clin Infect Dis 2021;72:1102-3.
DOI: https://doi.org/10.1093/cid/ciaa768
Fadel R, Morrison AR, Vahia A, et al. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis 2020;71:2114-20.
DOI: https://doi.org/10.1101/2020.05.04.20074609
Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase iib, placebo-controlled trial. Clin Infect Dis. 2020;72:e373-81.
Azienda Unità Sanitaria Locale Reggio Emilia. Patients E of the E of HD of M in S-C( C-19) P. No Evaluation of the Efficacy of High Doses of Methylprednisolone in SARS-CoV2 ( COVID-19) Pneumonia Patients (Unpublished results). Available from: https://clinicaltrials.gov/ct2/show/NCT04673162?term=Methylprednisolone&cond=Covid19&cntry=IT&draw=1&rank=1
Confalonieri M, Salton MF. Methylprednisolone vs. dexamethasone in COVID-19 pneumonia (MEDEAS RCT) (Unplublished results). Available from: https://clinicaltrials.gov/ct2/show/NCT04636671?term=Methylprednisolone&cond=Covid19&draw=2
Yadav H. Steroid dosing by bioMARker guided titration in critically ill patients with pneumonia (unpublished results). Available from: https://clinicaltrials.gov/ct2/show/NCT03852537?term=Methylprednisolone&cond=Covid19&draw=3
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473-5.
DOI: https://doi.org/10.1016/S0140-6736(20)30317-2
WHO. Clinical management of COVID-19: interim guidance. WHO, 27 May 2020. Available from: WHO/2019-nCoV/clinical/2020.5:1-62
Bellani G, Grasselli G, Cecconi M, et al. Noninvasive ventilatory support of COVID-19 patients outside the intensive care units (WARd-COVID). Ann Am Thorac Soc 2021;18:1020-6.
DOI: https://doi.org/10.1513/AnnalsATS.202008-1080OC
Coppadoro A, Benini A, Fruscio R, et 0061l. Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak. Crit Care 2021;25:80.
DOI: https://doi.org/10.1186/s13054-021-03502-y
Coen D, Paolillo C, Cavazza M, et al. Changing emergency department and hospital organization in response to a changing epidemic. Emerg Care J 2020;16:8969.
DOI: https://doi.org/10.4081/ecj.2020.8969
Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130:2620-9.
DOI: https://doi.org/10.1172/JCI137244
Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Sci 2020;368:473-4.
DOI: https://doi.org/10.1126/science.abb8925
Ahmed MH, Hassan A. Dexamethasone for the treatment of coronavirus disease (COVID-19): a review. SN Compr Clin Med 2020;2:2637–46.
DOI: https://doi.org/10.1007/s42399-020-00610-8
Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. J Heart Lung Transplant 2020;39:405–7.
DOI: https://doi.org/10.1016/j.healun.2020.03.012
Bahl A, Johnson S, Chen NW. Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients. Intern Emerg Med 2021;16:1593-603.
DOI: https://doi.org/10.1007/s11739-021-02655-6
Goleva E, Covar R, Martin RJ, Leung DYM. Corticosteroid pharmacokinetic abnormalities in overweight and obese corticosteroid resistant asthmatics. J Allergy Clin Immunol Pract 2016;4:357-60.e2.
DOI: https://doi.org/10.1016/j.jaip.2015.11.013
Meduri GU, Annane D, Confalonieri M, et al. Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. Intensive Care Med 2020;46:2284-96.
DOI: https://doi.org/10.1007/s00134-020-06289-8
Rafiullah M, Siddiqui K. Corticosteroid use in viral pneumonia: Experience so far and the dexamethasone breakthrough in coronavirus disease-2019. J Comp Eff Res 2020;9:1247-54.
DOI: https://doi.org/10.2217/cer-2020-0146
Li Y, Meng Q, Rao X, et al. Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study. Crit Care 2020;24:698.
DOI: https://doi.org/10.1186/s13054-020-03429-w
Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020;395:683-4.
DOI: https://doi.org/10.1016/S0140-6736(20)30361-5
Hashimoto S, Sanui M, Egi M, et al. The clinical practice guideline for the management of ARDS in Japan. J Intensive Care 2017;5:50.
DOI: https://doi.org/10.1186/s40560-017-0222-3
Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 2020;8:267-76.
DOI: https://doi.org/10.1016/S2213-2600(19)30417-5
Meduri GU, Siemieniuk RAC, Ness RA, Seyler SJ. Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. J Intensive Care 2018;6:53.
DOI: https://doi.org/10.1186/s40560-018-0321-9
Annane D, Pastores SM, Rochwerg B, et al. Correction to: Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESIC. Intensive Care Med 2018;44:474-7.
DOI: https://doi.org/10.1007/s00134-017-4951-5
Mueller AA, Tamura T, Crowley CP, et al. Inflammatory biomarker trends predict respiratory decline in COVID-19 patients. Cell Rep Med 2020;1:100144.
DOI: https://doi.org/10.1016/j.xcrm.2020.100144
Hariyanto TI, Japar KV, Kwenandar F, et al. Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis. Am J Emerg Med 2021;41:110-9.
DOI: https://doi.org/10.1016/j.ajem.2020.12.076
Ji P, Zhu J, Zhong Z, et al. Association of elevated inflammatory markers and severe COVID-19: A meta-analysis. Med (Baltimore) 2020;99:e23315.
DOI: https://doi.org/10.1097/MD.0000000000023315
Coppo A, Bellani G, Winterton D, et al. Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study. Lancet Respir Med 2020;8:765-74.
DOI: https://doi.org/10.1016/S2213-2600(20)30268-X
How to Cite
Vergnano, B., Calcinati, S., Signori, D., Benini, A., Pozzi, M. R., Verga, L., Pizzagalli, J., Bonfanti, P., Bellani, G., & Foti, G. (2021). Steroids in severe COVID-19 patients: A retrospective analysis on the first pandemics in Lombardy. Emergency Care Journal, 17(3). https://doi.org/10.4081/ecj.2021.9888
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
